BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC) Meeting Abstract


Authors: Kopetz, S.; Yoshino, T.; Kim, T. W.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T. S.; Eng, C.; Yaeger, R.; Desai, J.; Zhang, X.; Usari, T.; Mori, A.; Tabernero, J.
Abstract Title: BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Meeting Title: 2023 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 41
Issue: 16 Suppl.
Meeting Dates: 2023 Jun 2-6
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2023-06-01
Language: English
DOI: 10.1200/JCO.2023.41.16_suppl.TPS3627
PROVIDER: EBSCOhost
PROVIDER: cinahl
DOI/URL:
Notes: Meeting Abstract: TPS3627 -- Meeting was also available virtually -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Rona Denit Yaeger
    324 Yaeger